Skip to content

Probiotic Influence on Obesity-Related Lipidemia

The Efficacy and Safety of a Probiotic in Reducing Body Fat and Blood Lipids Among Overweight and Obese Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06305650
Enrollment
72
Registered
2024-03-12
Start date
2024-03-20
Completion date
2024-07-30
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight or Obesity

Keywords

Probiotic, Obesity

Brief summary

This study aims to investigate the effects of Bifidobacterium breve BBr60 on key health indicators in overweight and obese adults. Specifically, it will assess the probiotic's impact on body composition metrics such as BMI, body fat percentage, WHR, and BMR. The inclusion criteria for participants are a BMI of ≥28 kg/m\^2, targeting individuals who stand to benefit significantly from metabolic and body composition improvements.

Interventions

DIETARY_SUPPLEMENTProbiotic

Through oral probiotic intervention for 12 weeks, participants' BMI, body fat percentage, and waist-to-hip ratio will be measured at weeks 0, 6, and 12, and fecal samples will be collected at weeks 0 and 12 for gut microbiota analysis.

Sponsors

Wecare Probiotics Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Double(Participant,Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

1. Body mass index (BMI) ≥ 28 kg/m2; 2. Voluntarily, in writing, and signing the informed consent form, agreeing to participate in this study; 3. Those who agree to abide by the protocol and study restrictions and are able to comply with a low-carbohydrate, energy-restricted diet plan. 4. Subjects (including male subjects) have no plans to have children from 14 days before screening to 6 months after the end of the trial and voluntarily take effective contraceptive measures;

Exclusion criteria

1. Taking items with similar functions to those tested in a short period of time will affect the judgment of the results; 2. Patients with severe allergies and immune deficiency; 3. Women who are pregnant, breastfeeding or planning to become pregnant; 4. Severe diseases of cardiovascular, lungs, liver, kidneys and other important organs, diabetes, thyroid disease, severe metabolic diseases, malignant tumors, and severe immune system diseases; 5. People who have used antibiotics in the past two weeks; 6. Those who failed to consume the test samples as required or failed to follow up on time, resulting in uncertainty in determining the efficacy; 7. Have used laxatives or fiber supplements in the past 6 weeks; 8. Subjects judged by other researchers to be unfit to participate. Those who meet any of the above conditions will not be selected.

Design outcomes

Primary

MeasureTime frameDescription
Effect on body mass index (BMI) values.12 weeksAfter the probiotic intervention, the change in body mass index (BMI) from baseline in obese/overweight individuals will be calculated. BMI is measured by dividing a person's weight in kilograms by the square of their height in meters (kg/m\^2).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026